MXPA03003011A - Metodos para inducir muerte de celulas cancerosas y regresion de tumores. - Google Patents

Metodos para inducir muerte de celulas cancerosas y regresion de tumores.

Info

Publication number
MXPA03003011A
MXPA03003011A MXPA03003011A MXPA03003011A MXPA03003011A MX PA03003011 A MXPA03003011 A MX PA03003011A MX PA03003011 A MXPA03003011 A MX PA03003011A MX PA03003011 A MXPA03003011 A MX PA03003011A MX PA03003011 A MXPA03003011 A MX PA03003011A
Authority
MX
Mexico
Prior art keywords
methods
cancer cell
cell death
tumor regression
inducing cancer
Prior art date
Application number
MXPA03003011A
Other languages
English (en)
Inventor
George Q Daley
Original Assignee
George Q Daley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by George Q Daley filed Critical George Q Daley
Publication of MXPA03003011A publication Critical patent/MXPA03003011A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MXPA03003011A 2000-10-05 2001-10-05 Metodos para inducir muerte de celulas cancerosas y regresion de tumores. MXPA03003011A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23824000P 2000-10-05 2000-10-05
PCT/US2001/042509 WO2002028381A2 (en) 2000-10-05 2001-10-05 Methods of inducing cancer cell death and tumor regression

Publications (1)

Publication Number Publication Date
MXPA03003011A true MXPA03003011A (es) 2003-07-14

Family

ID=22897049

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03003011A MXPA03003011A (es) 2000-10-05 2001-10-05 Metodos para inducir muerte de celulas cancerosas y regresion de tumores.

Country Status (14)

Country Link
US (1) US6777415B2 (es)
EP (1) EP1322334A2 (es)
JP (1) JP2004510733A (es)
CN (1) CN1479630A (es)
AU (2) AU1186202A (es)
BR (1) BR0114430A (es)
CA (1) CA2424797C (es)
HK (1) HK1052870A1 (es)
HU (1) HUP0302913A3 (es)
MX (1) MXPA03003011A (es)
NO (1) NO20031531L (es)
NZ (1) NZ524936A (es)
WO (1) WO2002028381A2 (es)
ZA (1) ZA200302523B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6369138B2 (en) 1997-07-11 2002-04-09 Bridgestone Corporation Processability of silica-filled rubber stocks with reduced hysteresis
WO2008109417A1 (en) * 2007-03-02 2008-09-12 Case Western Reserve University Mgmt inhibitor combinations for the treatment of neoplastic disorders
AU2002211427A1 (en) * 2000-10-05 2002-04-15 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
US20040126755A1 (en) * 2001-08-29 2004-07-01 Stephan Dietrich A Gene expression based method for distinguishing metastatic from non-metastatic forms of a tumor, and use in designing therapeutic drugs
US20030185831A1 (en) * 2001-11-30 2003-10-02 Schering Corporation Methods of treating cancer using an FPT inhibitor and antineoplastic
JP2005515201A (ja) * 2001-12-03 2005-05-26 シェーリング　コーポレイション 癌の処置におけるｆｐｔインヒビターおよび少なくとも２つの抗腫瘍性剤の使用
US20050004008A1 (en) * 2002-03-01 2005-01-06 Frackelton A. Raymond SHC proteins as therapeutic targets in proliferative diseases
JP4694786B2 (ja) * 2002-03-01 2011-06-08 ロジャー・ウィリアムズ・ホスピタル 乳房、前立腺および卵巣の癌の予測のための、Ｓｈｃタンパク質に関連する方法および組成物
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
US7691905B2 (en) * 2002-12-24 2010-04-06 New York University Inhibition of melanogenesis and melanoma metastasis with p-aminobenzoic acid (PABA)
CA2544421A1 (en) * 2003-11-06 2005-05-26 Schering Corporation Combination of a farnesyl transferase inhibitor with an antihormonal agent for the treatment of breast cancer
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
US20070148660A1 (en) * 2005-06-16 2007-06-28 The Regents Of The University Of California Treatment of maladaptive substance use with H-ras antagonists
US20080255171A1 (en) * 2005-10-07 2008-10-16 Manley Paul W Combination of Nilotinib with Farnesyl Transferase Inhibitors
ATE521893T1 (de) * 2005-11-11 2011-09-15 Roger Williams Hospital P66-shc als prädiktiver marker bei der krebsbehandlung
CN102274513B (zh) * 2011-07-06 2013-02-20 南开大学 ERK1/2抑制剂通过刺激巨噬细胞干扰素γ表达抑制肿瘤生长
CN102626416B (zh) * 2012-05-11 2013-04-17 江苏省人民医院 他莫昔芬联合雷帕霉素、人参皂苷Rg3复合物在制备治疗肝癌药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU665341B2 (en) 1990-12-18 1996-01-04 Wellcome Foundation Limited, The Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
JP2000504023A (ja) 1996-04-03 2000-04-04 メルク エンド カンパニー インコーポレーテッド 癌治療方法
JP2000508335A (ja) * 1996-05-30 2000-07-04 メルク エンド カンパニー インコーポレーテッド 癌の治療方法
AU7953798A (en) 1997-06-17 1999-01-04 Schering Corporation Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives as farnesyl protein transferase inhibitors
CA2293706C (en) * 1997-06-17 2008-11-18 Schering Corporation N-substituted urea inhibitors of farnesyl-protein transferase
US6096757A (en) 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
WO2000042042A2 (en) 1999-01-11 2000-07-20 Princeton University High affinity inhibitors for target validation and uses thereof
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
ATE342054T1 (de) * 1999-04-14 2006-11-15 Dana Farber Cancer Inst Inc Verfahren und zusammansetzung zur behandlung von krebs
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
AU2001294511A1 (en) * 2000-06-30 2002-01-08 The Regents Of The University Of California New strategy for leukemia therapy
AU2002211427A1 (en) * 2000-10-05 2002-04-15 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors

Also Published As

Publication number Publication date
NO20031531D0 (no) 2003-04-04
CN1479630A (zh) 2004-03-03
US20020128280A1 (en) 2002-09-12
US6777415B2 (en) 2004-08-17
NO20031531L (no) 2003-06-05
WO2002028381A3 (en) 2003-03-27
HUP0302913A2 (hu) 2003-12-29
CA2424797C (en) 2009-12-29
HUP0302913A3 (en) 2005-05-30
BR0114430A (pt) 2004-01-06
AU1186202A (en) 2002-04-15
ZA200302523B (en) 2004-08-24
WO2002028381A2 (en) 2002-04-11
AU2002211862B2 (en) 2007-03-15
CA2424797A1 (en) 2002-04-11
HK1052870A1 (zh) 2003-10-03
JP2004510733A (ja) 2004-04-08
NZ524936A (en) 2005-08-26
EP1322334A2 (en) 2003-07-02

Similar Documents

Publication Publication Date Title
ZA200108258B (en) Methods of inducing cancer cell death and tumor regression.
MXPA03003011A (es) Metodos para inducir muerte de celulas cancerosas y regresion de tumores.
HUP0203968A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2001264559A8 (en) Cancer gene determination and therapeutic screening using signature gene sets
HK1080840A1 (en) Arylcarbonylpiperazines and heteroarylcarbonylpiperazines and the use thereof for treating benign and malignant tumour diseases
AU2003215460A8 (en) Cancer associated protein kinases and their uses
AU2001249549A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
EP1320376A4 (en) TREATMENT OF PROSTATE CANCER
HK1078585A1 (en) Water-soluble porphyrin platinum compounds with high tumor selectivity and their use for the treatment of benign and malignant tumor diseases
HUP0300005A3 (en) Modified cytokines for use in cancer therapy
MXPA03008582A (es) Agentes y metodos para tratamiento de cancer.
AU6395201A (en) Tumour suppressor and uses thereof
EP1316560A4 (en) NEW HUMAN HEAD CANCER ANTIGEN AND HIS GEN
GB0000993D0 (en) Cancer associated genes and their products
MXPA03000984A (es) Metodos para el tratamiento del cancer y el dolor asociado con el mismo utilizando antagonistas de endotelina.
EP1401494A4 (en) TUMOR THERAPY
IS6707A (is) Efnablanda til forvarna og meðhöndlunar á krabbameini
GB0026015D0 (en) Cancer treatment
ZA200203166B (en) Treatment of cancer.
AU2002218744A1 (en) Bax fragment induced tumor cell death
SI1165078T1 (sl) Postopki za induciranje smrti rakavih celic in regresijo tumorjev
AU2001297571A1 (en) Detection and treatment of prostate cancer
AU2002366364A8 (en) E2f and cancer therapy
AU2001289127A1 (en) Tumor treatment
AU2003262815A8 (en) New tumor suppressor genes and their uses

Legal Events

Date Code Title Description
FG Grant or registration